E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
The FDA has accepted Roche’s Biologics License Application (BLA) for vamikibart for the treatment of uveitic macular edema, with an approval decision expected by July 2027.
imphoenix82
Following confirmation of the PDUFA target action date of April 30, 2027, Kowa anticipates a US commercial launch of the K-911 glaucoma eye drop in the second half of 2027, subject to FDA approval.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
